



ABOUT AMGEN

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Our belief - and the core of our strategy - is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

AMGEN IN MALAYSIA

Amgen Malaysia is committed to serving patients by investing in science and biotechnology, and working with partners to ensure that patients stay healthier longer. Our ambition is to bring innovative and high-quality products to patients and promote healthcare systems that save costs and improve health. The Malaysia office was opened in 2019.

HEALTH INNOVATION THROUGH BIOLOGY AND GENETICS

Amgen is one of the world's leading biotechnology companies. We believe in a biology-first approach that permits our scientists to first explore the complex molecular pathways of disease before determining what type of medicine, or modality, is most likely to deliver optimal efficacy and safety. Amgen is making a difference by providing innovative medicines to combat cancer, cardiovascular disease and osteoporosis in Malaysia, and by continuing to pioneer new ways to stop diseases at their source.

BIOSIMILARS

We have over four decades of experience in biologics, which we are turning to making quality biosimilar medicines offering new treatment options for patients in therapeutic areas such as oncology and chronic inflammatory diseases. Our expertise extends from development to manufacturing, aiming to deliver a reliable supply. We use the same processes, scientific standards, and quality systems for our biosimilars as we do for our innovator biologics, always striving for the same high quality, reliability and comprehensive support services.

CHAMPIONING A PREDICT AND PREVENT APPROACH TO HEALTH

Amgen is working with partners to help shift health services away from helping people only when they get sick or break something, to those that predict and prevent instead. By harnessing big data and new technology, better understanding risk factors, raising awareness and developing better systems and services, it is possible to not only add years to people's lives but also to add life to their years.

Amgen is committed to collaborations across Malaysia to accelerate the shift of healthcare from a 'break and fix' model to a 'Predict and Prevent' model. Not only does this mean people stay healthier for longer, it also helps to stabilise healthcare and societal costs and improve patient access to medicines. In 2017, the first Fracture Liaison Service (FLS) was launched at Beacon Specialist Hospital, and subsequently in 2018 at Pusat Perubatan Universiti Kebangsaan Malaysia (PPUKM), followed by Pusat Perubatan Universiti Malaya (PPUM) in 2020 (expansion from previous FLS for hip fractures). Since then, there has been a marked improvement in diagnosis and management of these patients. Both FLS initiatives in Beacon Hospital and PPUKM had received silver awards from the International Osteoporosis Foundation. Amgen is also a corporate partner in the Bone Health Alliance Malaysia (BHAM) that was launched in 2021. BHAM consists of 3 key NGOs - The Osteoporosis Awareness Society of Kuala Lumpur and Selangor (OASKLS), Fragility Fracture Network Malaysia (FFNM), and Malaysian Osteoporosis Society (MOS), and aims to raise awareness and interest of osteoporosis among local communities.



AMGEN MISSION

To serve patients

AMGEN QUICK FACTS

Global Headquarters

Thousand Oaks, California

Staff

Approximately 20,000 worldwide

Stock Listing

NASDAQ: AMGN

Amgen Leadership

Colin Chan, General Manager, Amgen Singapore and Malaysia

Amgen Malaysia Address and Phone

Suite 9.01, Level 9, Menara Summit,
Persiaran Kewajipan, USJ 1, UEP,
Subang Jaya, Selangor 47600
(Tel) +603 8601 7161

Products Approved and Available in Malaysia

- AMGEVITA® (adalimumab)
- BLINCYTO® (blinatumomab)
- KYPROLIS® (carfilzomib)
- MVASI® (bevacizumab)
- NEULASTIM® (pegfilgrastim)
- NEUPOGEN® (filgrastim)
- PROLIA® (denosumab)
- REPATHA® (evolocumab)
- VECTIBIX® (panitumumab)
- XGEVA® (denosumab)

For more information on our pipeline and therapies, visit www.amgen.com